NCT00614835View on ClinicalTrials.gov

Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2001

Primary Completion Date

February 28, 2006

Study Completion Date

January 31, 2012

Conditions
Uterine LeiomyosarcomaUterine Cancer
Interventions
DRUG

Docetaxel plus Gemcitabine

Gemcitabine 900 mg/m2 IV over 90 minutes day 1 Gemcitabine 900 mg/m2 IV over 90 minutes day 8 + Docetaxel 75 mg/m2 IVPB day 8 Dexamethasone 8 mg po bid days 7-9 GCSF 150 ug/m2 (round to nearest vial size: 350 ug or 480 ug) SQ days 9-15 Repeat every 21 days for total of 4 cycles

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00614835 - Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus | Biotech Hunter | Biotech Hunter